ClinicalTrials.gov
public full text
Public Domain
Belumosudil and Rituximab for Primary Treatment of Chronic Graft-Versus-Host-Disease
This is an open-label, Phase 2 study designed to evaluate the safety and efficacy of belumosudil and rituximab as primary treatment of cGVHD.
Conceptio Open Archive
Analyze & explore related research in Conceptio
Connect this record directly into your research workflow or AI agent. Explore citations across open repositories, query full text, and export structured proof bundles.
This document is indexed with metadata only: full text is not available in the archive for this record. Open the official source ↗
Related documents
- Belumosudil for the Pre-emptive Treatment of Patients With Chronic Graft Versus Host Disease#859196
- Study of First Line Treatment of Chronic Graft Versus Host Disease With the Association of Ciclosporine, Corticosteroids and Rituximab (Protocol R-GVHD)#875182
- A Study of Belumosudil in Children With Chronic Graft Versus Host Disease (schoolROCK)#1010600
- CK0802 for Treatment of Steroid Refractory Graft vs. Host Disease (GVHD)#855928
- Efficacy and Safety of KD025 in Subjects With cGVHD After At Least 2 Prior Lines of Systemic Therapy#1095328
Record · ID 1170972
Retrieved via Conceptio: every document is proof-bundled with source, license, and retrieval metadata.
Retrieved via Conceptio: every document is proof-bundled with source, license, and retrieval metadata.
Bring this data into your agent: Connect via MCP or API · 20 free credits to start · no card required
Read the Docs → · View CLI source on GitHub · Conceptio Open Knowledge Archive
Read the Docs → · View CLI source on GitHub · Conceptio Open Knowledge Archive